AEDs - Free CE Continuing Education online pharmacy, pharmacists

More documents

Recommendations

Info

Lacosamide (Vimpat ® )• MOA:– Selective enhancement of sodium channel slow inactivation– Binds to collapsin response mediator protein 2 (CRMP-2)• FDA Approved Indication:– Adjunctive therapy in the treatment of partial-onset seizures in patient with epilepsy aged 17years and older.– Controlled substance (schedule yet to be determined)• Dosage:– Adjunct (partial seizure)• Oral: Initial dose: 50 mg ORALLY twice daily; increase weekly by 100 mg/day given in 2divided doses up to 200 to 400 mg/day• IV: Initial dose: 50 mg IV twice daily; increase weekly by 100 mg/day given in 2 divideddoses up to 200 to 400 mg/day; infuse over 30 to 60 minutes• Dosage Forms:– Tablet: 50 mg (pink), 100 mg (dark yellow), 150 mg (salmon), 200 mg (blue) film-coated tablets– IV Solution: 200 mg/20 mL single-use vial for intravenous use• Pharmacokinetics:– Not affected by food.– Renally eliminated; 300mg/day max for CrCl
Vigabatrin (Sabril®)• MOA: GABA-transaminase inhibitor• FDA Approved indications:– Adjunctive therapy for refractory complex partial seizures in adults– Infantile Spasm• Dosage:– Seizure:• Adults:Starting dose 1gm/day; maintenance dose 2-4gm/day• Children: Starting dose 40mg/kg/day in two divided doses; maintenance dose is80-100mg/kg/day– Infantile Spasm: 50-100mg/kg/day, divided twice daily• Dosage Forms:– Powder: Sabril® [CAN]: 0.5 g [not available in the U.S.]– Tablet: Sabril® [CAN]: 500 mg [not available in the U.S.]• Pharmacokinetics:– Absorption not affected by food– Renally eliminated (adjust dose for CrCl
Page 1 and 2: Understanding and ManagingEpilepsyJ
Page 3 and 4: Understanding and ManagingEpilepsyS
Page 5 and 6: Outline• Overview of the disorder
Page 7 and 8: Incidence of Epilepsy
Page 9 and 10: Success in AED RegimensSeizure free
Page 11 and 12: Comparative Pharmacokineticsof 1st.
Page 13 and 14: Gingival Hyperplasia Inducedby Phen
Page 15 and 16: Stevens-Johnson Syndromehttp://miss
Page 17 and 18: Trabecular Bone(http://www.merck.co
Page 19 and 20: Pharmacokinetics of Newer AEDsDrug
Page 21 and 22: Drug-Specific Side Effects:Newer AE
Page 23 and 24: Levetiracetam IV - Advantages• Ca
Page 25: Pharmacokinetic Model:Keppra XR Pla
Page 29 and 30: Benefits of Generic Antiepileptic D
Page 31 and 32: Treatment Considerations:What Would
Page 33 and 34: Current Treatment OptionsPartialGen
Page 35 and 36: What’s on the Horizon• Lamotrig
Page 37: Summary• Unrecognized drug intera

AEDs - Free CE Continuing Education online pharmacy, pharmacists

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?